# A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Source: https://onco.cc/trials/nct05751928/  
OnCo record `nct05751928` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing BCD-217 in melanoma, active and no longer recruiting.

## Summary

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma is a phase 3 interventional study registered as NCT05751928, led by Biocad, and active but no longer recruiting on the registry. Official title: A Randomised Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma. Planned enrolment is 411 participants (actual). The study started in 2023-04-05 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05751928
- Phase: 3
- Setting: A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma
- Sponsor: Biocad
- Enrolled: 411

## Sources

- ClinicalTrials.gov NCT05751928: https://clinicaltrials.gov/study/NCT05751928

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/)
- drugs: [BCD-217](https://onco.cc/drugs/bcd-217/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct05751928.json